NSPR InspireMD, Inc.
USHealthcareAs of 2026-07-10 16:00
Why NSPR matters now
InspireMD, Inc. (NSPR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.72 with +1.11% on the session and $33.7M in market capitalization; recent performance reads 1-month -29.00% and YTD -60.11%.
The latest financial table shown here is Q1 2026, with revenue of $3.4M, net income of $289.0K, and EPS of $0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -120.7%.
The latest indexable market news headline is "InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.50; recent insider activity includes Stuka Paul filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.20
P/S
3.07
EV/EBITDA
-0.68
DCF Value
$-5.25
FCF Yield
-120.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
28.1%
Operating Margin
-480.6%
Net Margin
-344.1%
ROE
-81.5%
ROA
-66.1%
ROIC
-108.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.4M | $289.0K | $0.00 |
| Q4 2025 | $3.1M | $-11.8M | $-0.14 |
| FY 2025 | $9.0M | $-48.8M | $-0.76 |
| Q3 2025 | $2.5M | $-12.7M | $-0.17 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.50
Target (Median)
$4.50
Target Range
$3.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
IL
Exchange
—
Beta
0.74
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.